InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.…
Here's Why InflaRx (IFRX) Is a Great 'Buy the Bottom' Stock Now
InflaRx (NASDAQ: IFRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 65 employees.
The shares were at 1.040 USD on 20 November 2026, down 28.8% over 52 weeks. Its 52-week range is 0.7980 USD to 2.949 USD: the price is 64.7% below the high and 30.3% above the low.
Its market capitalisation is 153.26M USD.
InflaRx reports return on equity of -109.8%.
It holds more cash than debt, a net cash position of 114.59M EUR. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.